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Mouse models indicate that metastatic dissemination occurs extremely early; however, the
timing in human cancers is unknown. We therefore determined the time point of metastatic
seeding relative to tumour thickness and genomic alterations in melanoma. Here, we ﬁnd that
lymphatic dissemination occurs shortly after dermal invasion of the primary lesion at a
median thickness of ~0.5 mm and that typical driver changes, including BRAF mutation and
gained or lost regions comprising genes like MET or CDKNA2, are acquired within the lymph
node at the time of colony formation. These changes deﬁne a colonisation signature that was
linked to xenograft formation in immunodeﬁcient mice and death from melanoma. Thus,
melanoma cells leave primary tumours early and evolve at different sites in parallel. We
propose a model of metastatic melanoma dormancy, evolution and colonisation that will
inform direct monitoring of adjuvant therapy targets.
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The classical linear progression model
1 holds that metastases
are generated from late-disseminating clones that geneti-
cally resemble the predominant clone of the primary
tumour (PT)2,3, whereas parallel progression suggests dis-
semination from early transformed lesions and acquisition of
important genetic changes at the metastatic site1. Parallel pro-
gression gained substantial support by patient data4,5 and trans-
genic mouse models6–8, indicating that metastatic dissemination
often occurs early. In mouse models, molecular mechanisms of
early dissemination were identiﬁed and evidence was provided for
a superior metastatic potential of early disseminated cancer cells
(DCCs) compared to late DCCs9,10. In patients, comparative
sequencing of PTs and metastases revealed branched parallel
progression in all cases tested, whereas no case followed linear
progression11. However, since clinical practice often derives
therapy decisions from an assumed (based on a linear progression
model) identity between accessible PTs and inaccessible meta-
static seeds, a correct understanding of metastatic progression is
essential. Surprisingly, despite high relevance for adjuvant
therapies, which need to take into account the molecular het-
erogeneity of DCCs and PTs12, no study has ever investigated the
relative time point of dissemination during tumour progression
or assessed the evolutionary events during the early steps of
metastasis, i.e., early colonisation, within target organs of patients.
In this study, we address both aspects in melanoma and lymph
node metastasis because (i) overtly visible melanoma is often
detected when tumour thickness is measured in micrometres,
unlike late-detected cancers whose diameter is recorded in the
range of centimetres and (ii) we recently developed a highly
sensitive assay based on disaggregation and immunocytology to
detect disseminated cancer cells in the sentinel lymph node
(SLN). We demonstrated in more than 1000 patients13 that this
method outperforms conventional histopathology and that gp100
is best suited (considering sensitivity and speciﬁcity) to detect
melanoma cells13,14. We now apply this assay to detect, isolate
and characterise early metastatic seeds and their molecular pro-
gression. We ﬁnd that dissemination occurs very early and that
early DCCs need to acquire important genetic alterations outside
the PT to form metastatic colonies in patients or in xenografts.
Moreover, we identify for each DCC alteration the most likely site
of its acquisition.
Results
Tumour thickness at dissemination and colony formation. To
determine melanoma thickness at seeding and colonisation, we
examined the clinical data from our previous studies13,14, where
we had established and validated a gp100-based detection method
for single melanoma cells in SLNs of 1027 patients with clinically
node-negative disease as assessed by palpation and ultrasound. Of
these, 51% harboured gp100-positive cells13, whereas we did not
detect a single gp100-positive cell among 70 control samples.
Genetic analysis showed that 98% of randomly selected gp100-
positive cells from SLNs harboured DNA sequence changes13.
There was a weak positive correlation (Spearman’s ρ = 0.18, p
< 0.0001, n = 1027) between PT thickness and disseminated
cancer cell density (DCCD; deﬁned as the number of gp100-
positive cells per million cells in disaggregated SLNs). The
percentage of patients with gp100-positive SLNs increased only
marginally from T1 (≤1 mm) to T4 (>4 mm) tumours (T1:
45.8%, T2: 47.4%, T3: 54.9% and T4: 59.4%), suggesting that
dissemination occurs preferentially early. We used the nonpara-
metric Turnbull method to determine thickness at dissemination
and compared ﬁve different parametric models for best ﬁt. While
all models largely concurred (Table 1a), a standard log-logistic
model outperformed the other approaches (Table 1a). These
analyses revealed that (i) lymphatic dissemination was restricted
to 65.2% of all patients and that (ii) in 50% of these cases cancer
cells had spread before tumours reached a thickness of 0.5 mm
(95% CI: 0.3–0.7 mm; Fig. 1a). In sum, our data show that ~1/3 of
all melanomas disseminated lymphatically at a tumour thickness
of <0.5 mm, ~1/3 at a thickness ≥0.5 mm and ~1/3 were not
capable of lymphatic spread.
We asked at what tumour thickness DCCs would have grown
to a colony in SLNs. In all cases, we split the SLNs and analysed
one half by histopathology (preserving the architecture) and the
other by gp100 immunocytology after disaggregation (destroying
the architecture but enabling quantiﬁcation; for details, see ref.
Table 1 Identiﬁcation of best ﬁtting model for tumour thickness at dissemination and colonisation
(a) Tumour thickness at dissemination
Distribution Asymptote (%) Asymptote 95% CI FPA (%) TD at FPA
(mm)
95% CI FPA
(mm)
No of parameters p valuea BICb
Standard log-
logistic
65.2 60.4–70.0 32.6 0.5 0.3–0.7 2 0.671 718.7
Exponential 58.1 55.2–61.0 29.0 0.5 0.4–0.7 2 0.604 719.5
Weibull 63.5 53.5–73.4 31.7 0.4 0.04–0.8 3 0.581 725.5
Log-normal 65.9 51.5–80.2 32.9 0.5 0.04–0.8 3 0.572 725.6
Fréchet 71.2 47.5–94.9 35.6 0.6 0.05–0.9 3 0.567 725.7
(b) Tumour thickness at colonisation
Distribution TD15 colonisation
(mm)
95% CI TD15
(mm)
TD50 Colonisation
(mm)
95% CI TD50
(mm)
No of parameters p valuea BICb
Exponential 2.4 2.0–3.1 10.3 8.4–13.0 1 0.31 210.1
Standard log-
logistic
2.4 1.9–3.1 13.4 10.5–17.1 1 0.28 210.8
Fréchet 2.3 1.9–2.8 11.1 7.3–21.4 2 0.32 215.4
Log-normal 2.4 2.0–2.9 9.7 6.9–17.0 2 0.25 215.6
Weibull 2.5 2.0–3.1 8.9 6.8–14.2 2 0.18 216.0
FPA 50% of asymptote, TD tumour thickness, TD15 tumour thickness at 15% colonisation, TD50 tumour thickness at 50% colonisation, CI conﬁdence interval, BIC Bayes information criterion
aFor goodness of ﬁt comparing model predictions with observed values (see methods)
bLowest BIC identiﬁes best model
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13). To establish a DCCD representative for colonisation, as
opposed to early dissemination (ﬁrst arrival), we compared both
halves of a patient’s SLN. Analysing histopathological detection
rates vs. DCCD for 494 patients14, we had noted before that
histopathological detection of cancer cells was associated with a
DCCD of 100 in 50% of cases (see ref. 14). We therefore analysed
65 unselected, consecutive cases with a positive DCCD of up to
100, expecting that ﬁrst colonies may become detectable slightly
below this value. We assessed whether the SLN half screened by
standard and immune histopathology contained so called isolated
tumour cells (ITC; <0.2 mm or <200 cells) or larger lesions, i.e.,
micrometastases (Fig. 1b and Supplementary Fig. 4a). Of the 65
cases, 50 (77%) were negative by standard and immune
histopathology, 10 (15%) harboured ITC and 5 (8%) micro-
metastases. Interestingly, the median DCCD of histopathologi-
cally negative and of ITC samples were 1 and 4, respectively,
whereas micrometastatic lesions displayed a median DCCD of 74
in the half analysed by immunocytology (Fig. 1c). Thus, it seems
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safe to conclude that colonisation, understood as micrometastasis
formation, occurs at a DCCD of ~100, whereas samples with
lower DCCD comprise melanoma cells before colony outgrowth.
Of the 525 DCC-positive patients, the proportion of samples
with a DCCD> 100 increased with tumour thickness. An
exponential distribution function provided best ﬁt (Fig. 1d and
Table 1b). Median thickness at colonisation (10.3 mm) was about
20 times higher than at seeding. We noted that the risk of de novo
tumour seeding steadily decreased as tumours grew, while the risk
of de novo colonisation did not depend on tumour thickness
(Fig. 1e)
Discrepancy between dissemination and survival. Patients with
T1 and T4 stage melanomas differed by only 13.6% for gp100-
positive SLNs (38/83 (45.8%) vs. 79/133 (59.4%), respectively). To
explore how this marginal difference in DCC positivity is linked
to survival, we asked how many patients had died during the
median follow-up period of 49 months (range, 3–123 months),
with 370 (36%) patients having a follow-up of ≥5 years. Only 1/83
(1.2%) DCC-positive T1 stage melanoma patient died, consistent
with previous studies15,16. In contrast, 47/133 (35.3%) of T4 stage
cases harbouring DCCs died (Fig. 1f; 9-year survival 88.9% for
T1, and 45.9% for T4; p< 0.0001, log-rank test). Thus, there is a
discrepancy between T1 and T4 stage melanomas regarding
seeding and death. Nevertheless, for the total cohort of patients,
each DCC increased the risk of death13.
Genetic lineages of PTs and DCCs. The standard approach to
addressing outcome-associated differences between T1 and T4
melanomas employs PT tissue. It assumes that the molecular
characteristics of metastasis-initiating DCCs can be identiﬁed
using the PT, because PTs and DCCs are thought to be largely
identical. To test this assumption, we compared the genomic
proﬁles of PTs and their matched DCCs from SLNs.
We ﬁrst assessed the genomes of disseminated melanoma cells
in a subset of 61 patients (Supplementary Fig. 1 and
Supplementary Table 1) of which high-quality genomic DNA of
DCCs was available for molecular analysis (in total, 91 individual
DCCs). Inclusion criteria are summarised in Supplementary
Fig. 1. The malignant origin of each included DCC was conﬁrmed
by comparative genomic hybridization (CGH; Fig. 2a) or targeted
sequencing for BRAF/NRAS. DCCs were found to display a large
range of copy number variations ranging from 1 to 52 per cell
(Fig. 2a; median = 14; interquartile range = 14.8). We noted that
genomic gains per cell (median = 9; range, 0–39) were more
frequent than losses (median 3.5; range, 0–21). As a control, we
isolated 30 single leukocytes and performed CGH analysis
(Supplementary Fig. 2) with none of the control cells displaying
any aberration (p< 0.0001; Fisher’s exact test).
Next, DNA from available PTs of these patients was isolated by
laser microdissection (Supplementary Fig. 4b) and whenever
possible several areas were analysed. However, compared to other
cancers such as kidney cancer17, early stage melanomas are very
small, often technically precluding the assessment of subclones
from different areas. Microdissected PT samples (n = 23, 19
patients) and micromanipulator-isolated single DCCs (n = 24, 19
patients) were analysed by CGH (Supplementary Fig. 3).
Regardless of melanoma thickness, there was a striking disparity
between PTs and matched DCCs (Fig. 2b). Unexpectedly, PTs
from different individuals clustered closer together than indivi-
dual PTs and their matched DCCs (Fig. 2b and Supplementary
Fig. 5). Interestingly, PTs displayed signiﬁcantly more deletions
than DCCs (Fig. 2b, c and Supplementary Fig. 5; p = 0.003,
Mann–Whitney U test). The corresponding difference in gains
was clearly nonsigniﬁcant (p = 0.66, Mann–Whitney U test).
When several areas from the same PTs were available, we noted
genomic heterogeneity, however they still clustered together (for
example 28T, 30T and 09T in Fig. 2b and Supplementary Fig. 5)
apart from their paired DCCs.
The observed disparity between PTs and DCCs may result
from two scenarios: (i) the isolated DCCs represent hidden
subclones within the PT that still exist at the time of surgery and
from which dissemination may have occurred late (scenario 1) or
(ii) the DCCs disseminated early and represent genomic states
that have become extinct within the primary site by later selective
sweeps (scenario 2). We investigated the 19 matched patient
samples assuming that each DCC derives from one of the PT
areas selected according to highest similarity (i.e., maximum
support for scenario 1; see 'Methods' section for details). For
deﬁning a detection threshold, we supposed that an aberration
must be present in at least 60% of cells in the corresponding PT
sample analysed by CGH18. To obtain a conservative estimate of
how many of our DCC samples could derive from DCC-identical
subclones within the PT, i.e., conform to scenario 1, we derived
maximum DCC subclone percentages that are still consistent with
the respective PT bulk measurement results for all loci.
Depending on the individual patient, these maximum percentages
ranged between 10 and 40%. We then calculated the maximum
number of DCCs that could derive from the hidden clones on an
α = 0.05 signiﬁcance level. We found that a maximum of 11/24
DCC samples could possibly result from DCC-identical subclones
within the PT if their corresponding subclone fractions are indeed
maximal, i.e., equal 10–40% depending on the individual patient
(Fig. 2d). In case of rarer DCC subclones, one must assume that
they disseminate several fold more successfully than the
remaining (i.e., non-DCC like) PT clones. For example, if a
DCC subclone displays a ﬁvefold higher successful dissemination
propensity, it may not exceed a frequency of 12.4% for the same
maximum of 11/24 subclone-derived DCCs. Consequently, SLN
Fig. 1 Dissemination of melanoma cells as function of tumour thickness. a Yellow function: estimated cumulative probability of dissemination as a function
of tumour thickness (Turnbull) (n= 1027 patients). Blue line: Standard log-logistic distribution incorporating a fraction of patients without long-term
dissemination (95% CI: blue dashed lines). Upper black dashed line: only 65.2% of melanomas disseminate lymphatically (95% CI: 60.4–70.0%). Fifty
percent of this value (32.6%) provides the median thickness (0.5 mm, 95% CI: 0.3–0.7 mm) of disseminating melanomas (lower black dashed line). b
Comparative analysis of histopathological and immuncytological SLN halves. Displayed are representative examples with immunocytological scores of
DCCD≤ 100, 100<DCCD≤ 1000 and DCCD> 1000. Samples LN 72 and LN 89 are stained against melan A LN 10, LN 135 and LN 168 against S100. LN
154 shows a highly pigmented melanoma in H&E staining. A close-up of the subcapsular region 3 is shown in the main ﬁgure; more central or core regions 1
and 2, see Supplementary Fig. 4a for higher magniﬁcation. c Evaluation of histopathological ﬁndings in corresponding sections of samples with a positive
DCCD< 100. d Percentage of DCC-positive patients (n= 525) with colonisation (DCCD> 100) according to the Turnbull estimate (yellow). The
percentage of colonisation (blue curve, 95% CI blue dashed curves) is described by a cumulative exponential distribution function (median 10.3 mm; 95%
CI: 8.4–13.0 mm). e Hazard functions for dissemination (yellow line), and colonisation (blue line) describing the instantaneous risk per unit thickness for an
event (dissemination, n= 1027; colonisation, n= 525) for those tumours, for which it has not yet occurred (de novo dissemination/ colonisation). f Survival
analysis of melanoma patients (n= 1027) according to T stage (T1:≤ 1 mm (n= 83); T2: 1.01–2.0mm (n= 496); T3: 2.01–4.0 mm (n= 315); T4: >4mm
thickness (n= 133); log-rank test, p< 0.001)
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DCCs, displaying the identiﬁed karyotypes, may equally likely
result from both scenarios, i.e. late dissemination from rare PT
subclones (scenario 1) or and early dissemination (scenario 2)
followed by selective extinction or somatic progression of the
disseminating clone. However, if the DCC-like subclones indeed
make up less than the respectively estimated maxima of 10–40%
of PT cells and display a dissemination ability similar to the
predominant (non-DCC-like) PT clones, the late dissemination
scenario 1 becomes increasingly unlikely.
We then reconstructed the phylogeny of PTs and their
matched DCCs based on the assumption that (1) aberrations
more common among samples have developed earlier in time and
(2) the overall number of genomic changes leading to the
observed sample data is minimal (maximum parsimony).
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Fig. 2 gp100-positive cells from SLNs and primary tumours display multiple copy number alterations (CNAs). a Ninety-one DCCs from our patients were
selected according to QC criteria (see main text and Supplementary Figure 1) for CGH and mutation analysis. Histograms depict the genomic gains (yellow)
or losses (blue) per cell. The identiﬁers indicate cell ID. b Cluster analysis of paired PTs (n= 23 samples) and DCCs (n= 24 samples) from 19 patients for
chromosomal aberrations (gain= +1; loss= −1). Only the 10 most variable regions are included (see Supplementary Figure 5 for all 53 variable regions). Side-
line identiﬁers indicate patient ID, sample type (PT and DCC) and sample index; bottom-line labels indicate chromosomal regions. Black (28T), white (30T)
and dark grey (09T) ﬁlled squares indicate examples of PT-DCC pairs for which several areas of the PT were available. Examples of paired DCCs and PTs
with varying PT thickness are indicated by coloured squares (green: 1 mm, grey: 1.4mm, pink: 2 mm, blue: 7 mm PT thickness). c Comparison of paired PTs
and DCCs for chromosomal aberrations. Displayed are the 18 chromosomal regions that differ signiﬁcantly (FDR-adjusted Fisher’s exact test p value ≤0.05)
between paired PTs (n= 23, 19 patients) and DCCs (n= 24, n= 19 patients) regarding aberration frequency. Gains and losses are given in percent. d
Maximum number of DCC samples NDCC (colour-coded) that cannot be excluded to derive from corresponding DCC-like clones within the PT plotted
against the assumed DCC-like clone fraction in the PT and the successful dissemination fold change. If DCC-like and non-DCC-like PT clones disseminate
equally (fold= 1), at most 11/24 DCC samples may result from DCC clones within the PT at the maximum indicated clone fraction of 0.40 (A); for twofold
dissemination not more than 14/24 (B). For fold= 5, the same number of samples can be excluded up to a fraction of 0.124 (11/24) (C) and 0.21 (14/24)
(D), respectively. These intermediate fractions correspond to a maximum of 5/24 (0.124) (E) and 7/24 (0.21) (F) DCC samples, respectively, if clones
disseminate similarly (fold= 1). See 'Methods' section for details. Signiﬁcance level α= 0.05 (Poisson-binomial distribution)
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Applying this approach to our copy number alteration (CNA)
data, we observed three types of phylogenetic trees (Fig. 3)
deﬁned by the number of branching points. In all 19 matched
samples, DCCs and PT samples branched early and evolved in
parallel (Fig. 3 and Supplementary Figs. 6–8).
DCCs and PTs are rarely clonal for BRAF mutations. Since
BRAF and NRAS mutations are frequent in melanoma, occurring
in 40 and 21% of cases on average, respectively19, we investigated
whether PTs pass them on to DCCs. We performed a series of
control experiments on single cells from cell lines, xenografts and
PTs to determine the allelic drop-out (ADO) rate for mutant and
wild-type alleles. We assumed one mutant and one wild-type
allele per cell and found the ADO rate for BRAF to range between
0% (mutant allele; 86/86 alleles detected) and 8% (wt allele; 79/86
alleles detected; Fig. 4a, b) and for NRAS between 0% (wt allele;
43/43 detected) and 2% (mutant allele; 42/43 detected). We
concluded that our single-cell assay is well suited to address
questions of clonality and lineage descent for BRAF and NRAS. In
matched patient samples, BRAF was mutated more frequently in
PTs (34%) than in DCCs (15%; p = 0.012, Fisher’s exact test; n =
32 patients; Fig. 4c and Supplementary Fig. 11), whereas no sig-
niﬁcant difference was observed for NRAS mutations (15% in PTs
and 11% in DCCs; p = 0.58; n = 29 patients). For these two
oncogenes, we found a shared wild type in 47%, a shared mutated
status in 16% and disparate mutational states in 37% of cases
(Fig. 4c). Among patients with mutated PTs, matched DCCs were
mostly not sharing these mutations (shared in 3/11 for BRAF and
3/6 for NRAS, Supplemental Fig. 12), indicating that they had
disseminated before ﬁxation of the mutation within the primary
site.
BRAF and NRAS mutations have been suggested to initiate
melanoma20 and, consequently, be fully clonal. We therefore
determined if sibling DCCs, i.e., individual DCCs from patients
with BRAF or NRAS mutant gp100+ DCCs of whom we could
isolate more than one DCC, all share the same mutation. We
found that sibling gp100+ DCCs are heterogeneous in 50 and
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Fig. 3 Phylogenetic trees of paired PT and DCC samples. Representative examples for the three distinct groups observed in our data (for all 19 patients, see
Supplementary Figures 6–8). The ordinate of the tree panels indicates the number of aberrations per CGH proﬁle (square root scale). Heat maps show
aberration proﬁles along paths from normal cells (N) to PT (P1–4) and DCC (D1, D3) samples, respectively. Proﬁles A1, A2 and A5 denote inferred
common ancestors (intermediates) (see 'Methods' section)
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57% of cases for BRAF and NRAS mutations, respectively
(Fig. 4d). To rule out a selective effect of the detection marker
gp100, we analysed additional melanoma DCCs detected by the
melanoma marker MCSP (melanoma-associated chondroitin
sulphate proteoglycan) and obtained similar results (Fig. 4d).
To test whether this heterogeneity of sibling DCCs reﬂects
method-induced mutant allele loss or non-clonality, we compared
the mutation rates of sibling DCCs with single cells (n = 86 for
BRAF and 43 for NRAS) from our control experiments (Fig. 4b).
In the latter, we detected the mutant allele in all (BRAF) or all but
one (NRAS) single cells, whereas the mutant allele often remained
undetected in gp100+ or MCSP+ DCCs (p< 0.0001 for BRAF; p =
0.0001 and 0.0004 for NRAS and gp100 and MCSP, respectively;
Fig. 4d). Therefore, the frequent failure to detect the mutant allele
in sibling DCCs cannot be explained by a technical artefact. We
conclude that BRAF or NRAS mutations among sibling DCCs are
not fully clonal. Finally, when we compared the mutational state
for PT-DCC-metastases triplets or pairs of PTs-metastases or
pairs of DCC-metastases, we found that DCCs with and without
BRAF/NRAS mutations were able to form manifest metastases
(Supplementary Fig. 12a, b).
In summary, both copy number alterations and targeted
mutation analysis demonstrate that primary melanomas and their
paired DCCs are largely genetically disparate implying early
evolutionary branching. Consequently, we focused on the
evolution of DCCs within the SLN because of their obvious
relevance for systemic cancer progression.
Genomic evolution of DCCs outside the PT. DCCs disseminate
early and display genomes either representative of earlier
evolutionary states before loss of chromosomal material (Fig. 2b,
c) or of a hidden PT subclone. To address cancer evolution
outside the PT, we ﬁrst investigated the genomic proﬁles of DCCs
that had not yet expanded within the SLN and representing the
time early after arrival.
Since colony formation became clearly apparent at a DCCD> 100
(Fig. 1b and ref. 14), we considered samples with a DCCD ranging
from 1 to 99 to contain early arriving DCCs. Thus, DCCs from the
34 patients with a DCCD below 100 were categorised as thin and
thick melanomas taking the median thickness as a split (Fig. 5a). We
found no difference in the number of CNAs (total; gains; losses)
between DCCs arriving from thick and thin melanomas (Fig. 5a) and
could not identify any genetic alteration that was signiﬁcantly
enriched in DCCs from thick melanomas (Fig. 5b). Therefore, we can
exclude a simple model of mutation accumulation and late arising
metastasis-causing alterations within growing PTs.
We investigated for all genetic changes of SLN DCCs their
association to PT thickness and DCCD assuming that alterations
may either be acquired within the PT before dissemination or
thereafter. Since the risk of acquiring genetic changes is linked to
the number of cell divisions and the local environment, we
determined for each alteration whether the risk depends on the
number of cell divisions within the PT or the SLN. Strikingly, we
could classify most of the genetic changes into one of four
categories associated with the angle of a straight line that best
separates DCC samples with different aberration status in the
two-dimensional space of thickness and DCCD (Figs. 6a, d, g, j
and 7a; and 'Methods' section). The risk of acquiring category 1
changes (Fig. 6a–c) is solely related to the number of cell divisions
a cell undergoes within the PT before dissemination (nT) while
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subsequent cell divisions within the SLN (nL) do not alter
(increase or decrease) their emergence (Fig. 6a–c). Notably, all
changes acquired under the linear progression model conform to
this category. Category 2 (Fig. 6d–f) comprises alterations whose
risk is fully explained by the total number of cell divisions, i.e., the
generation of changes is independent of the microenvironment
and reﬂects total disease duration if growth rates within and
outside the primary are equal. As an example, initial gain of
chromosome 1p11–13 was 're-normalised' over time and
vanished as PTs grew larger than 2.7 mm (Fig. 6e, f). Category
3 changes (Fig. 6g–i) have a higher risk of emergence within the
SLN than within the PT. A striking example here is mutant BRAF,
which is rarely found in very small primary lesions21,22, but is
highly associated with the emergence of SLN colonies (Fig. 6h, i).
Thus, although BRAF mutations are present in ~1/3 of PTs in
paired PT-DCC samples (Fig. 4c), BRAF-mutated PT cells
obviously do either not disseminate or not engraft in SLNs.
Finally, we identiﬁed alterations, whose risk was negligible for the
number of cell divisions within the PT before dissemination but
dramatically increased at colonisation of the distant site (category
4, Fig. 6j–l).
In contrast to category 1 (exclusive dependence on the number
of cell divisions before dissemination) and category 2 (depen-
dence on the total number of divisions), categories 3 and 4 show a
real and observable dependence on the number of divisions
within the SLN, i.e., the DCCD. To identify critical DCCD values,
we scanned for the emergence of DCCD-dependent genomic
changes. Of note, alterations in regions harbouring typical
melanoma-driving onco- and tumour suppressor genes such as
BRAF or CDKN2A (9p21-p24) emerged at a DCCD of 77–106,
exactly when we noted morphological colony formation (Fig. 7b
and Supplementary Tables 2 and 3). NRAS mutation was
associated with insigniﬁcant classiﬁcation FDR values and the
best classiﬁer for NRAS separated out only 4 out of 87 samples. In
Figure 7a we required a minimum of 10 samples per class and
displayed in Figure 7b only loci reaching 5% signiﬁcance. Thus,
NRAS does not surface in either graphics. Obviously, cell
divisions within the SLN determine the risk of acquiring
alterations. Therefore, we compared labelling indices for the
proliferation marker Ki-67 in SLN DCCs from patients with
DCCD ≤ 100 and DCCD> 100, i.e., before and after colony
formation (Fig. 7c). As double staining of MIB-1 (anti-Ki-67) and
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HMB45 (anti-gp100) was unsuccessful, we replaced gp100 with
the melanoma-associated marker Melan A14. Ki-67 expression
was assessed in 37 nodes with DCCD ≤ 100 (Group A) and 21
nodes with DCCD> 100 (Group B), involving evaluation of 937
cells in total. In Group A, 11.4% of cells were clearly cycling ,
while 22.0% were in the cell cycle in group B (p = 0.0005; Fisher’s
exact test, Fig. 7c). Thus, a basal proliferation rate may initially
enable acquisition of genetic alterations that subsequently drive
accelerated outgrowth.
Colonisation-associated alterations and malignant behaviour.
Cancer cells forming a SLN colony displayed a characteristic
signature of alterations. To test whether pre- and post-colonising
DCCs have tumour-initiating ability, we transplanted both DCC
types and cells from cell lines into NSG mice. We ﬁrst evaluated
conditions for xenotransplantation of few melanoma cells23. For
cell line cells (Supplementary Fig. 13a, b) and patient DCCs (Fig.
8a, b), we compared two approaches: direct transplantation of
groups of DCCs and transplantation of DCC spheres after brief
culture under melanosphere conditions (Fig. 8a). We found that
melanospheres formed tumours in immunodeﬁcient NSG mice
earlier and more frequently than groups of single cells (p<
0.0001, log-rank test; Fig. 8b and Supplementary Fig. 13a, b). The
applied conditions supported growth from as few as a single
transplanted sphere or a group of seven DCCs (Fig. 8b). We
therefore only transplanted spheres from samples with DCCD ≤
100 and spheres or groups of single DCCs from samples with
DCCD> 100 for comparing the tumour-initiating ability of
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DCCs from SLNs with DCCD ≤ 100 to those with DCCD> 100.
The number of spheres per injected site was similar in both cases
(p = 0.39, Mann–Whitney U test; Fig. 8c). Strikingly, a DCCD>
100 was predictive of successful xenotransplantation (11/39
(28.2%) transplantations gave rise to tumours in 6/10 patients),
whereas samples with DCCD ≤ 100 never established tumours (0/
14 injection sites in 0/5 patients; Fig. 8c; p= 0.03, Fisher's exact
test). Genetic ﬁngerprinting conﬁrmed patient origin (Supple-
mentary Fig. 13c). Furthermore, in 5/6 patient-derived xenografts
either BRAF mutation, loss of 9p21–24 (harbouring CDKN2A), or
gain of 7q21–36 (harbouring MET) was present (Fig. 8d). In one
case (patient 125 in Fig. 8d), successful outgrowth was linked to
the presence of an NRAS mutation.
Finally, we explored whether the genetic aberrations associated
with colony formation in the SLN or with tumour formation in
mice were associated with clinical outcome. For this, we tested if
one or several alterations of our ﬁnal colonisation signature
(comprising BRAF mutation, loss of 9p21–24, gain of 7q21–36
and NRAS mutation) in single DCCs increased the risk of death.
Indeed, one or several of the signature changes were present in
DCCs of 8/9 (89%) patients dying from melanoma (p = 0.048, log-
rank test; Fig. 8e), with BRAF mutation being the most relevant
single indicator (p = 0.031).
Discussion
This study provides a compelling molecular model that accounts
for the ectopic evolution in the spread of early systemic cancer.
We report the ﬁrst estimate for the tumour extent at which
metastatic dissemination of a human cancer occurs; it is based on
highly sensitive, direct detection of DCCs rather than being
inferred from tumour growth rates24–26. The median thickness of
seeding melanomas was 0.5 mm (95% CI: 0.3–0.7 mm), much
smaller than previously thought.
We therefore speciﬁcally investigated the fate of early DCCs
and collected all available evidence to differentiate between three
possible scenarios. Model 1: early DCCs (here deﬁned as DCCs
before evidence of colony formation in the SLN) inherit all
genetic changes from the primary lesion that enable them to form
a metastatic colony. Model 2: early DCCs may exist but are
irrelevant; only late DCCs that disseminate after acquisition of
driver mutations within the PT, grow out to manifest colonies.
Model 3: early DCCs are genetically immature and acquire critical
alterations after homing to a distant site and thereby gain the
ability to form a colony.
Our data allow us to reject model 1. Despite clear evidence for
dissemination from earliest lesions, the 9-year death rate for T1
melanomas was much lower than the seeding rate at this stage. In
contrast, seeding and death rates in T4 melanomas were similar.
In line with this, pre-colonising DCCs lacked typical melanoma
driver changes and were unable to form xenografts. Therefore,
dissemination is necessary but not sufﬁcient to generate lethal
metastasis.
To address model 2, we ﬁrst compared PTs and DCCs. We
focused on CNAs because they best reﬂect cancerous progression
as opposed to point mutations4,20,27, which are frequently
detected also in benign lesions unlike CNAs4,20,28. Independent
of tumour thickness, CNA proﬁles of PTs and matched DCCs
were clearly different. Primary tumours displayed a differential
loss of chromosomal material and phylogenetic analysis indicated
that PTs and DCCs branch off early and progress in parallel,
rendering model 2 unlikely. To corroborate this reasoning, we
scrutinised DCCs that had just arrived in the SLN and speciﬁcally
compared DCCs from thin vs. thick melanomas. We tested
whether we can detect late-disseminating, genetically more
mature, possibly more aggressive cells in SLNs from patients with
thick melanomas. However, early DCCs from thin and thick
melanomas did not differ characteristically, neither with regard to
the number nor the quality of alterations.
Our analysis ﬁnally refuted model 2 and supported model 3
when we determined for each DCC alteration its link to the
number of cell divisions within and outside the PT and visualised
the aberration status as a function of tumour thickness and
DCCD. Most changes were found to fall into one of four cate-
gories (category 1: exclusive dependence on the number of cell
divisions before dissemination; category 2: dependence on the
total number of cell divisions before and after dissemination;
category 3: higher impact of cell divisions in SLN; category 4:
exclusive dependence on the number of cell divisions after dis-
semination). Only 29% of loci showing signiﬁcant FDR values
correspond to category 1 and their alteration may thus derive
from linear progression. The great majority (71%), however,
conform to category 2 (18%), 3 (18%) or 4 (36%) that are in an
increasing degree inconsistent with linear progression. Had, e.g.,
BRAF mutations been persistently generated within the primary
and continuously spread to the SLN, a positive mutation status at
small DCCD values would have been a frequent observation in
Fig. 6i. Since, however, BRAF mutations existed in ~1/3 of PT
samples while being absent in precolonizing DCCs, BRAF mutant
cells either remain in the primary, are unable to survive in or
bypass the sentinel. Recent ﬁndings support the ﬁrst explanation
because strong oncogene activation apparently favours pro-
liferation, but impedes dissemination10,21,29. Consistently, most
of our experimental data cannot be explained by the linear pro-
gression paradigm stating that genetic alterations originate
Fig. 6 DCCs acquire genetic alterations within and outside the PT. a, d, g, j Genome alterations are explained by four different risk scenarios. Panels a, d, g
and j show different risk functions E (colour-coded) as a function of the number of cell divisions in the SLN (nL) and the PT (NT). The two arrows indicate a
prototypic state trajectory: initially, cell divisions exclusively occur within the PT (NT> 0, nL= 0) until after nT cell divisions a tumour cell disseminates to
the SLN. Subsequently, PT and SLN cells grow simultaneously (NT> 0, nL> 0). The grey dashed horizontal lines at NT= 14.4 and 26.6 correspond to the
minimum (0.6 mm) and maximum (10mm) experimental thickness values ('Methods' section). Growth rates are presumed equal in both environments
implying (i) inaccessibility of the region below the diagonal (grey solid line), consistent with the empty lower right triangular area in c, f, i, l and (ii) NT= nT
+ nL (after dissemination; 'Methods' section). The angle indicates the direction of the normal vector regarding equal risk lines. b, e, h, k Classiﬁcation results
for four prototypic CGH results (loci/mutations) using linear classiﬁers with 2D set points according to the indicated DCCD and PT thickness values and
directions as pictured by the small arrows within each rectangle of the colour matrix ('Methods' section). Colour encodes the negative decadic logarithm of
the FDR-corrected p values of each classiﬁcation (Fisher’s exact test). Basically, the red/orange areas separate regions differing in their distribution of
genomic alterations. Their orientation parallels the equal risk lines in a, d, g, j. DCCD and thickness values were chosen according to experiment while
classiﬁer set points were slightly displaced relative to these values (white points included for the 5% most signiﬁcant FDR values). Minimum FDR values
are indicated by black points. N= 87 DCCs, 57 patients, 82 loci/mutations. c, f, i, l Corresponding measurement results as well as the class assignments of
the best (lowest FDR) classiﬁers indicated by the light (class1) and dark (class2) grey areas. The class boundary does not necessarily appear linear as
samples are listed according to rank while linear classiﬁcation was performed in log(DCCD)-log(thickness) space. The classiﬁer angle and the distribution
of deletions (−1), balances/wt (0) and ampliﬁcations/mutations (+1) in each class are given in the title
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exclusively from the primary. Instead, our alternative hypothesis
that most alterations, including BRAF mutation, are preferentially
generated within the SLN post dissemination (conforming to
parallel progression) is in distinctly and visibly better agreement
with our experimental observations. Interestingly, acquisition of
category 3 and 4 changes was associated with DCCDs of 77–106,
exactly when colony formation became morphologically evident.
Thus, early DCCs arrive immaturely and progress within the SLN
(model 3).
Our transplantation experiments strongly support this con-
clusion. Acquisition of these changes by DCCs was associated
with xenograft formation in mice, whereas early DCCs (DCCD<
100) failed to form tumours, consistent with DCC immaturity.
DCCD> 100 was linked to colony formation in the SLN and a
signiﬁcant increase in mean Ki-67 proliferation index from 11 to
22%, conﬁrming basal proliferation and indicating the acquisition
of advantageous changes. Interestingly, the mean proliferation
index of 11% before colonisation resembles that of T1 melanomas
at transition to the tumorigenic vertical growth phase (VGP),
previously found to range between 9 and 13%22. Thus, early SLN
DCCs display progression-enabling growth rates.
Our model (model 3) is fully supported by previous analyses.
BRAF mutations were found in 0 and 10% of in situ and early
radial growth phase (RGP) melanomas, respectively 30,31. When
the VGP starts, melanomas expand in the dermis (i.e., become
tumourigenic), often acquire BRAF mutations 30,31, and increase
their proliferation rate22. DCCs in the SLN and possibly other
metastatic sites apparently re-capitulate this process during
colonisation. Our genomic data and mathematical analyses of
dissemination and colonisation indicate that after PT cells
acquired a proliferative phenotype, de novo dissemination
becomes increasingly unlikely, as evidenced by hazard rates for de
novo dissemination diminishing with increasing tumour thick-
ness. Also, BRAF and NRAS mutations in PTs were rarely present
in matched DCCs, indicating that BRAF/NRAS mutant clones
were less likely to seed than to expand. All ﬁndings cohere to a
model of a largely parallel passage through the 'Vogelgram'32 of
melanoma cells at the primary and secondary sites (Fig. 9). The
initial disparity between PTs and DCCs regarding BRAF
mutations, in addition to the strong selective advantage this
mutations endows DCCs with during colony formation, explains
both the observed disparity for BRAF mutations between PTs and
metastases31,33–35 and the increased frequency of BRAF muta-
tions in metastases compared to early RGP melanomas.
Evolution outside the PT is consistent with a large sequencing
study comparing PTs and matched metastasis from various
cancers11, where linear progression was never observed. However,
it should be noted that most cancer phylogeny models apply the
'inﬁnite sites assumption'36–38, stating that each mutation is
generated maximally once39, which is not justiﬁed in cancer. For
example, melanoma of unrelated patients converge on the clas-
sical BRAF-V600E mutation in 40% of cases. Therefore, it is
unreasonable to exclude a priori that two clones of the same
cancer acquire the BRAF-V600E mutation independently. Our
single-cell analysis supports previously reported evidence40 that
current models of branching evolution as deduced from
sequencing studies of bulk tumours still underestimate the
complexity of cancer evolution by relying on the inﬁnite sites
model.
It remains to be explored in more detail why high T stage is a
risk factor in melanoma. The correlation between tumour
thickness and colonisation may suggest that PTs facilitate colo-
nisation by secreted factors41. Such factors may act in a dose (i.e.,
tumour volume)-dependent manner, either directly upon DCCs
or indirectly by altering the microenvironment locally or sys-
temically. Formal proof of this scenario would require model
systems that enable genomic in vitro progression from immature
to mature cancer cells triggered by supporting factors. Such
models are currently not available. The lack of adequate sup-
porting signals from the PT may explain why we failed to observe
engraftment of pre-colonising cells in NSG mice, that rarely
thrive, neither in mice nor in humans, after early melanoma
removal.
Our ﬁndings have implications for the development of adju-
vant therapies. First, novel drugs may be required to eradicate the
metastatic seed prior to colonisation, as pre-colonising DCCs may
lack typical drug targets. Second, this also applies to the identi-
ﬁcation of neo-antigens in DCCs to develop adequate immune
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strategies against metachronous metastasis. Last but not least, we
will need suitable assays to monitor molecular evolution during
occult disease.
Methods
Patients. We used data from 1027 melanoma patients from Tübingen with
clinically node negative (as assessed by palpation and ultrasound) melanoma who
underwent tumour resection and sentinel node biopsy to describe the association
between thickness and melanoma spread13. Molecular studies and BRAF/NRAS
mutational survival analysis included patients recruited in Tübingen and Regens-
burg. Informed written consent was obtained from all patients. The study was
approved by the ethics committees of the Universities Tübingen (ethics vote
number 5/99) and Regensburg (07-079).
Cell lines. The melanoma cell lines A375 and MelHo were used (obtained from the
Leibniz Institute DSMZ-German Collection of Microorganisms and Cell cultures)
and their identity veriﬁed by short tandem repeat (STR) analysis (Cell-ID™,
Promega). MelHo is listed in the ICLAC database for mis-identiﬁed cell lines due
to unclear patient origin, but was used as the cell line is heterogenic for the exon 15
mutation c1799T>A (BRAF). The cell lines 70–61 and 102–4 were developed from
DCC-derived xenografts and are exon 15 mutation c1799T>A (BRAF) and exon 3
mutation c181C>A (NRAS) mutated, respectively, as determined by Sanger
sequencing (Sequiserve, Vaterstetten, Germany). Their patient origin was veriﬁed
by STR analysis (Cell-ID™, Promega), their melanoma origin by a human
pathologist and their aberrant genotype by CGH. A375 and MelHo were main-
tained in DMEM, 10% FCS, 100 U/ml penicillin, 0.1 mg/ml streptomycin; 102–4
and 70–61 in RPMI, 10% FCS, 100 U/ml penicillin, 0.1 mg/ml streptomycin. All
cell lines were routinely tested for mycoplasma and were found to be negative.
Controls. Control lymph nodes (n = 70) were obtained from 60 non-melanoma
patients (47 skin-draining nodes from non-malignant conditions, 6 SLNs from
non-melanoma skin cancer patients and 17 nodes from non-small cell lung cancer
patients). Lymph nodes were halved and then either ﬁxed (for histopathology) or
disaggregated without ﬁxation, stained and evaluated identically to the melanoma-
derived SLNs. After screening 2 × 106 lymphocytes, the control lymph node status
was revealed to the observer, and screening of the samples was continued until
completion, unlike to the melanoma patient samples.
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Fig. 8 Tumour-forming ability of DCCs before and after colonisation and patient survival. a Left to right: Isolated MCSP+ DCCs from a patient-SLN; DCC-
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patients, 15 injection sites) from the same patient into NSG mice. Left: Kaplan–Meier analysis of tumour-free mice (p< 0.0001, log-rank test). Right:
number of injected MCSP+ DCCs and DCC-derived spheres per injection site. Black ﬁlled circles indicate tumour formation. c Number of MCSP+ DCCs
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transplanted into NSG mice. Each circle represents one injection site. Black ﬁlled circles indicate tumour formation (engraftment). The p value (p= 0.03
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colonisation signature from Fig. 7a and Supplementary Table 3 (i.e., loss of genetic locus 9p21–24 and gain of 7q21–36, BRAFmut and NRASmut), n= 6
patients. Note that samples 125 and 277 add NRAS mutations to the colonisation signature. e Left: Kaplan–Meier survival analysis of patients with DCCs
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not (wt regarding colonisation signature, n= 22). Right: Kaplan–Meier survival analysis of patients with DCCs that display BRAF mutation (BRAFmut, n=
15) or wild type sequence (wt, n= 46)
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Lymph node disaggregation and immunocytology. Quantitative immunocytol-
ogy was performed as described13,14 after SLN biopsy using unﬁxed SLN tissue.
Brieﬂy, the lymphatic tissue was cut into 1-mm pieces and disaggregated
mechanically into a single-cell suspension by rotating knives (DAKO Medi-
machine, DAKO), washed with HBSS (Life Technologies, Heidelberg, Germany)
and centrifuged on a density gradient made of a 60% Percoll solution (Amersham,
Uppsala, Sweden). Cells were counted using a Neubauer counting chamber. Per
slide, 106 cells from the interphase were then given onto adhesion slides (Menzel,
Braunschweig, Germany) in a volume of 1 ml PBS. After sedimentation for 1 h, the
slides were air-dried overnight. Immunocytological staining was carried out with
the alkaline phosphatase/anti-alkaline phosphatase method using primary anti-
bodies against gp100 (HMB45, 0.7 µg/ml, catalogue number M0634, DAKO) and
as primary antibody and 5-bromo-4-chloro-3-indolyl phosphate/NBT (DAKO) as
substrate, yielding a blue reaction product. A SLN was deﬁned as gp100 positive if
it contained at least one gp100-positive cell. The number of positive cells per
million lymphocytes was recorded. Positive samples were stored for a maximum of
4 days in PBS at 4 °C until cell isolation for whole-genome ampliﬁcation. For the
isolation of living DCCs, single cells were stained with an anti-human MCSP
(melanoma chondroitin sulphate proteoglycan, clone 9.2.27, catalogue number
554275, BD Pharmingen, 25 µg/ml) according to the manufacturer's recommen-
dations and detected by indirect immunoﬂuorescence (goat anti-mouse-Cy3, cat-
alogue number 115-166-071, Jackson, 15 µg/ml). After washing, MCSP+ cells were
isolated using a micromanipulator (Eppendorf PatchMan NP2) and transplanted.
Comparison between single cells and sphere transplantations. Single cells of
disaggregated SLNs were plated in 6 cm poly-HEMA (12 mg/ml, Sigma-Aldrich)-
coated cell culture plates (Sigma-Aldrich) at a density of 200,000 viable cells/ml.
Cells were grown in a serum-free DMEM/Ham’s F12 basal medium (PAN Biotech
GmbH), supplemented with 100 U/ml penicillin, 0.1 mg/ml streptomycin (both
PAN Biotech GmbH), 0.5% BSA (VWR-Biochemical), 10 µg/ml insulin (Sigma-
Aldrich), 10 nM HEPES (Sigma-Aldrich), 1 × B27 (Life Technology GmbH), 10 ng/
ml EGF (Sigma-Aldrich) and 10 ng/ml bFGF (Sigma-Aldrich), 4 μg/ml heparin
(Sigma-Aldrich), 5 ng/ml GRO-α (R&D Systems), 20 ng/ml HIL-6 (kindly pro-
vided by S. Rose-John) and 0.2% methylcellulose (Sigma-Aldrich). Cultures were
incubated at 37 °C and 5% CO2 and 7% O2. Sphere growth was weekly monitored.
To generate spheres from melanoma cell lines (MelHo, A375 maintained in
DMEM, 10%FCS, 100 U/ml penicillin, 0.1 mg/ml streptomycin), single cells were
plated at a density of 10,000 viable cells/ml on poly-HEMA (12 mg/ml)-coated cell
culture plates in the same medium as for SLN cells, but without HIL-6 and GRO-α.
Spheres were isolated manually.
Xenotransplantation. Spheres or MCSP+ cells from disaggregated SLNs were
collected using a micropipettor or micromanipulator and pooled in a microwell
(volume 10–15 µl, Terasaki). Microwells were pre-coated over night with 12 mg/ml
poly-HEMA (Sigma-Aldrich) at RT. Single cells were transplanted in a ﬁnal
volume of 30 µl and 25% high-concentration matrigel (BD Biosciences) as pub-
lished before23. Cells were injected with an insulin syringe (Microﬁne, 29 G, U-50,
BD Biosciences) subcutaneously into NOD.Cg-Prkdcscid IL2rγtmWjl/Sz (NSG,
6–8 weeks old, males and females). Mice were purchased from the Jackson
Laboratory and maintained under speciﬁc-pathogen-free conditions, with acidiﬁed
water and food ad libitum in the research animal facilities of the University of
Regensburg, Germany. All approved experimental animal procedures were con-
ducted to German federal and state regulations (Government of Upper Palatinate
or Lower Franconia). Mice were palpated every week at the site of injection.
Melanoma origin of xenografts was veriﬁed by a human pathologist and patient
origin was authenticated using STR analysis (Cell-ID™, Promega). Due to the
whole-genome ampliﬁcation (Klein et al., 1999) of samples prior to STR analysis,
which includes restriction digest by Mse I, only the STR loci TH01, D21S11,
D5S818, D13S317, D16S538 and vWA can be used for detection. Ampliﬁed frag-
ments were detected using 3100-Avant Genetic Analyzer (Applied Biosystems).
Fragment sizes were determined manually using Cell™ ID Allelic Ladder and
Cell™ ID Bins 1.0 provided by Promega.
Ki-67 labelling of DCC. For immunoﬂuorescence staining, cells were incubated
with primary antibodies against Melan A/MART-1 (clone A103, rabbit monoclonal
dilution 1:100, 11 µg/ml, catalogue number 281M-86, Sigma) and Ki-67 (clone
MIB-1, mouse monoclonal, catalogue number M7240, DAKO, 1.6 µg/ml) overnight
at 4 °C. As secondary antibodies, we used Alexa Fluor 555 (donkey anti-rabbit,
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Fig. 9 Model of melanoma progression from local to metastatic disease. Histologic appearance, patient-derived dissemination estimate, proliferation rate
and BRAF mutational state are integrated into the scheme. Data are taken from this study and from references22, 30, 31
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Thermo-Fisher-Scientiﬁc/Invitrogen, catalogue number A-31572) and Alexa Fluor
488 (donkey anti-mouse, Thermo-Fisher-Scientiﬁc/Invitrogen, catalogue number
A-21202). The nucleus was stained with DAPI (blue), Melan A with Alexa Fluor
555 (red) and Ki-67 with Alexa Fluor 488 (green). Counterstaining was performed
with 4′d-diamidino-2-phenylindole (DAPI) in mounting medium (Vector,
Vectashield).
DNA extraction and microdissection of PT areas. Areas for DNA extraction
were marked by a pathologist (P.R.) and subsequently extracted from parafﬁn-
embedded tumour blocks. The PALM microbeam system (Bernried) was used for
microdissection and catapulting. DNA from microdissected areas was isolated as
described in the section whole-genome ampliﬁcation.
Whole-genome ampliﬁcation. Whole-genome ampliﬁcation (WGA) from single
cells or microdissected tissue DNA was performed as previously described and is
described therein in detail42,43. The method is now commercially available as kit
(Ampli1, Silicon Biosystems).
Comparative genomic hybridisation. CGH of single cells and microdissected
tissue was performed as previously described and is described therein in detail42,44.
For most samples we used chromosomal CGH, as it is a very robust method, well
established for single cells, and for some samples array CGH. We carefully com-
pared both methods and found a good agreement between array CGH and chro-
mosomal CGH when applied to same samples44. While aCGH may detect more
changes (mainly for aberrations <10Mb), the overall picture for aCGH and cCGH
is very similar. For cases where we used aCGH, the resolution was adjusted to that
of cCGH.
Phylogeny of PTs and DCCs. For phylogenetic tree inference an independent
method was developed because present methods are targeted either at two-valued
mutation data45,46 or major–minor (allelic) copy numbers from SNP arrays or
sequencing47. Brieﬂy, phylogenetic trees were generated by assuming ideal (i.e.,
error free) data and inferring plausible common ancestors (intermediates) of
aberration proﬁles in matched samples by extracting shared features of an
increasing number of samples, i.e., evaluating common aberrations of sample pairs,
triplets, quads, etc., and organising these ancestors according to hierarchical levels.
Subsequently, admissible edges were constructed top–down between vertices
allowing for at most two relosses of acquired gains and no regains of any losses
(these conditions are also ensured globally for each path). Then, all simple paths
from the normal cell to the samples were generated using the igraph R-package
(version 1.0.1), combined into a directed acyclic graph (DAG) and ﬁltered for
fewest genomic changes along the graph and lowest number of intermediates
(maximum parsimony). While different ‘equal length’ DAG solutions are generally
possible using this approach, for the investigated samples all computations resulted
in unique tree structures. For an illustration of the method and comparison to the
inﬁnite sites model, see Supplementary Figure 9.
DCC sampling model. Basics: A DCC may derive from a minority clone of the PT
that is overlooked by our CGH measurement for the bulk PT sample. Metaphase
CGH requires 60% of cells in a sample to show an ampliﬁcation (deletion) to be
detected18. This corresponds to a limiting mean allele frequency of 2 + 0.6 (2–0.6).
Thus, a maximum of 40% of cells may be balanced although an aberration has been
detected for the whole PT sample. This percentage is reduced to 20% if the min-
ority clone has an opposing aberration. The general problem statement is to ﬁnd
DCC-like PT clone fractions fk k ¼ 1; ¼ ;Mð Þ, with M the number of measured
DCCs, and non-DCC-like clone allele frequencies Ci i ¼ 1; ¼ ; Lð Þ, with L the
number of measured loci, for which the composite mean allele frequency Pi ¼
1Pk fk
 
Ci þ
P
k fkDki falls within the interval range measured for locus i of the
bulk PT sample, i.e., one of the intervals I1 ¼ ½1; 1:4, I2 ¼ ð1:4; 2:6Þ or I3 ¼ ½2:6; 3
(Supplementary Figure 10). Here, we presuppose that single cells show hetero-
zygous alterations only, corresponding to the DCC measurement data Dki
assuming values 1 (deleted), 2 (balanced) or 3 (ampliﬁed). Each non-DCC-like PT-
clone allele frequency Ci can be the average of different (unmeasured) clones and
thus may take any real value in the interval [1,3]. Notably, fk = 0 for all k is always a
solution since Ci can be freely chosen to match the measured interval range. If
multiple vectors f
*
¼ f1; ¼ ; fMð Þ fulﬁll the above requirements we chose the one
with the maximum product
Q
k fk to obtain a conservative estimate for DCC origin
from DCC-like PT clones (see also ‘Computation’ below). If multiple loci are
present, valid vectors f
*
need to be determined across all loci prior to selection
according to maximum product. The 19 patients for whom matched PT-DCC
measurements were available comprised 23 PT and 24 DCC samples. Speciﬁcally,
there were 13 patients with one PT and one DCC sample, i.e., T;Dð Þ ¼ 1; 1ð Þ, and
3, 1, 1 and 1 patients with T;Dð Þ ¼ 1; 2ð Þ; 2; 1ð Þ; 3; 1ð Þ and (2,3), respectively. We
assumed that each DCC derives from one of the matched PT samples and tested all
TD assignment possibilities per patient ﬁnally choosing the one with the maximum
product of fractions (conservative estimate, see above). This resulted in 5, 9 and 10
DCCs with maximum clone fractions of f1 ¼ 0:1, f2 ¼ 0:2 and f4 ¼ 0:4, respec-
tively. For Fig. 2d, DCC clone fractions were scaled per sample according to
f si ¼ fi  sði ¼ 1; 2; 4Þ with s running from 0 to 1 while the reference x ¼ f4  s is
displayed on the x axis, e.g. when f s4 for a sample with maximum fraction fmax ¼
0:4 increases from 0 to 0.4, f s1 for a patient with fmax ¼ 0:1 rises from 0 to 0.1.
Differential dissemination: We assumed that different tumour cell clones can
have different rates of successful dissemination and denoted by d the ratio (fold
change) of DCC-like/non-DCC-like successful dissemination. Accordingly, the
clonal fraction of the DCC with index i in the SLN is given by
pi ¼ dfi= 1þ ðd  1Þ
P
k fk
 
.
Computation: In case of only one unique value p for all N = 24 DCC samples,
the probability of independently picking n DCCs derived from the corresponding
DCC-like PT clone is given by the binomial probability
pr nð Þ ¼ b N; nð Þpn 1 pð ÞNn , with b the binomial coefﬁcient. The minimum
number of samples n* that can be excluded to derive from DCC-like clones
according to signiﬁcance level α = 0.05 can be calculated according to
1Pl<n? pr lð Þ  α. The maximum number of samples that cannot be excluded
on the same α-level is then one less. If different DCCs have different fractional
values pk k ¼ 1¼Mð Þ, the probability for n successes is given by the Poisson-
binomial distribution pr nð Þ ¼PA2FðnÞ
Q
i2A pi
Q
j2AC ð1 pjÞ, in which F(n) is the
set of all subsets of n integers out of 1; ¼ ;Mf g and AC is the complement of A
regarding 1; ¼ ;Mf g. Since F(n) contains M!=ðn! M  nð Þ!Þ elements it can be
very large, e.g. F 12ð Þj j  2:7  106 for M = 24. We thus used the discreteness of the
occurring fractional values, i.e. the fact that the 24 fractions take at most 1  K  6
different values. The probability for n successes can then be rewritten as
pr nð Þ ¼Pi¼1;¼ ;L
Q
k¼1¼K b N k½ ; n½i; kð Þpn i;k½ k 1 pkð ÞN k½ n i;k½  , in which the ith
row n i; ½  of the L × K partition matrix n ; ½  denotes the ith partition of n into K
integers not exceeding the respective class numbers N[k] (gtools R-package, version
3.5.0).
Tumour growth model. Spherical tumours of diameter 0.6 and 10 mm may
contain N0:6 ¼ 2:2  104 and N10 = 108 tumour cells, respectively, assuming a
melanoma cell diameter of 18 μm48 and a tumour cell fraction of 60%49. Inter-
estingly, this corresponds to the volume fractions of 52% for simple cubic and of
74% for hexagonal close spherical packing. In an exponential growth model,
tumours of diameter 0.6 and 10 mm result from log2ðN0:6Þ ¼ 14:4 and log2ðN10Þ ¼
26:6 cell divisions as indicated in Fig. 6a, d, g, j.
DCCD thickness model. Principle: We assume exponential growth kinetics for
both the PT and the SLN colony starting from a single-cell, i.e., the number of
PT cells is given by MT ¼ 2gT t and in the SLN cells obey ML ¼ 2gLðttLÞ, with tL  t
the time of dissemination to the SLN (start of growth). The base-2 logarithm ofMT
and ML indicates the respective number of cell divisions, i.e., NT ¼ gTt for the PT
and nL ¼ gL t  tLð Þ for the SLN. The number of cell divisions within the PT
incurred by cells eventually disseminating to the SLN is given by nT ¼ gTtL. We
propose a model, in which cell divisions within the PT or within the SLN can have
a differential inﬂuence on the occurrence of genomic alterations, a notion that is
also supported by recent literature50. Accordingly, we deﬁne a corresponding risk
function
E ¼ anT þ bnL ¼ aNT þ b ag^ð ÞnL
with g^ ¼ gT=gL the ratio of growth rates and nT ¼ NT  g^nL. Based on our
experimental observations, we consider four major categories of genomic altera-
tions. First, alterations whose risk of occurrence exclusively depends on the number
of cell divisions within the PT before dissemination. Accordingly, setting a = 1 and
b = 0 leads to E ¼ NT  g^nL implying that curves of equal risk E ¼ E0 ¼ constð Þ
are ascending lines y ¼ E0 þ g^x in the x–y plane x ¼ nL; y ¼ NTð Þ. Second, we
regard alterations for which the total number of cell divisions is most important,
i.e., irrespective of the environment. Here, a = b = 1 results in E ¼ nT þ nL. For
equal growth rates (i.e., g^ ¼ 1), this scenario corresponds to risk proportional to
the number of PT cell divisions (i.e., E =NT) and thus horizontal equal risk lines.
Third, we include alterations for which cell divisions within the SLN are con-
siderably more important than in the PT. Accordingly, for a = 1 and b ¼ 2g^ the risk
becomes E ¼ NT þ g^nL resulting in descending equal risk lines y ¼ E0  g^x.
Fourth, we account for alterations for which the number of cell divisions within the
SLN are most decisive. Here, choice of a = 0 and b = 1 results in E = nL and thus
vertical equal risk lines. Referring to our previous work13 alterations falling into the
third category appear most important for patient survival. Notably, we do not
presently differentiate between risk of gain and loss (die out) of alterations.
Linear classiﬁers: Linear classiﬁcation was performed in scaled log(DCCD)-log
(thickness) space, i.e., log values were scaled to the unit interval independently for
each variable. Each classiﬁer consisted of a 2D set point p ¼ ðscl:DCCD; scl:thickÞ
of scaled logarithmic DCCD and thickness values and an angle φ 2 ½0; 180Þ
specifying the direction of the classiﬁer’s normal vector. 2D set points were chosen
according to the experimental DCCD and thickness values but displaced by ±δ/2
with δ the minimal absolute difference between the experimental DCCD and
thickness values, respectively. This resulted in 4 displacement set points per DCCD
thickness pair and enabled unequivocal classiﬁcation of each sample. Angles were
scanned as per 1° step size. Classiﬁcation was performed by constructing difference
vectors between all experimental values and the set point and evaluating the sign of
the corresponding scalar products regarding the normal vector. Classiﬁcation
results were assessed by applying Fisher’s exact test to the corresponding 2 × 2 or
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2 × 3 contingency tables and FDR-adjusted p values were calculated across 82 loci/
mut. In Fig. 6b, e, h, k, only the lowest FDR value across displacement set points
and angles is displayed for each DCCD-thickness pair. The mapping between log
(DCCD) and the number of cell divisions in the SLN is basically qualitative. To
arrive at maximum classiﬁer angles of about 135° as predicted by theory in case of
equal growth rates g^ ¼ 1ð Þ, we derived corrected angles according to re-scaling the
log(DCCD)-axis by a factor of 1/2. Finally, large angles near 180° were transformed
to small angles near 0° by subtracting 180° (Fig. 7a).
Sample weights: Multiple DCCs from a single individual may tend to be more
similar to each other than do DCCs derived from different patients. This can be a
confounding factor when analysing patient collectives, in which the number of
DCCs per patient varies. A commonly applied corrective are patient weights, i.e.
coefﬁcients wi = 1/ni that down-weight samples according to the number (ni) of
samples of patient pi. The effective number of samples available for statistical
analysis is then calculated as M ¼Pi¼1¼ P wini , here equalling the number of
patients P. Generally, P is smaller than the sum of measured samples N ¼P
i¼1¼ P ni implying that statistical power is lost in this approach if multiple
patient samples are at least partially representative of the whole population. We
thus aimed at increasing sample weights within an admissible range deﬁned by
high equivalence of the corresponding distributions of genomic features.
Speciﬁcally, we compared the distribution of ampliﬁcations (+1), balances (0) and
deletions (−1) for genomic loci l between the patient weight and our admissible
weight model. In our model, weights are maximised within the range
1=ni  wl;i  1, while the corresponding p value of statistical testing is kept above a
limiting value (p = 0.95). For spatial sample classiﬁcation (here, regarding regions
within the DCCD-thickness plane) it is important that the distributional
equivalence holds both globally and locally. As a consequence, we conducted global
tests enclosing all samples, as well as local tests deﬁned by k nearest patient
neighbours (k = 5). Numeric computation in R was time intensive and thus
parallelised using the R-packages foreach (version 1.4.3) and doParallel (version
1.0.10). The use of genomic locus-speciﬁc weights can be justiﬁed by the fact that
patient DCC clonality can be locus-speciﬁc (Hoffmann, Klein, et al., unpublished
results). We note that the power approach to equivalence testing, which requires
sufﬁcient (80%) power for detecting some reasonable difference δ in addition to a
high p value of difference testing has been invalidated51,52. Different equivalence
testing methods have been proposed in the literature, the most prominent being the
family of two one-sided-tests (TOST)52,53. Nevertheless, there appears to be only
one method54 addressing contingency tables, which, moreover, is restricted to 2 × 2
tables and the χ2 test. Here, we dealt with 2 × 3 tables and applied Fisher’s exact test
because of low case numbers. We could thus not employ present equivalence
testing procedures. While these tests are appealing from a theoretical point of view,
they still have their own unsolved problems regarding e.g. the choice of an
appropriate margin δ (speciﬁcally for contingency tables) or issues concerning the
rejection region52. Nevertheless, we expect sample weights resulting from
difference testing as applied in this study to be largely similar to corresponding
results of future expanded equivalence testing methods. Sample weights apply to
the results shown in Figs. 5b, 6, 7a, 7b.
Fisher’s exact test for non-integer tables: χ2 testing is advised against if
contingency table entries are small (<5), which applies to our data since deletions
were often rare. Moreover, we used testing as a means to evaluate classiﬁcation
results, for which some zero case numbers are actually desired, e.g. for the off-
diagonal elements of 2 × 2 contingency tables. Fisher’s exact test is unrestricted
regarding case numbers but can only be applied to integer tables. To make Fisher’s
method available for non-integer analysis (sample weights), we chose to interpolate
the p values of neighbouring integer contingency tables as follows. Let r be the
number of non-integer entries of a contingency table that are summarised in an
r-dimensional vector vr. We construct an r-dimensional simplex sr that is rooted at
the integer-rounded vector [vr] and is directed towards vr. Subsequently, the Fisher
test p values corresponding to the r + 1 integer vertices of the simplex are calculated
and used to linearly approximate the p value of the contingency table.
Mutation analysis of BRAF and NRAS. Mutations in NRAS and BRAF genes were
detected using Sanger sequencing (Sequiserve, Vaterstetten, Germany) after gene-
speciﬁc ampliﬁcation from WGA samples. The primers for BRAF exon 15 analysis
were as follows: forward 5′-TCCAGACAACTGTTCAAACTG-3′ and reverse 5′-
CTCTTCATAATGCTTGCTCTG-3′, encompassing the mutations of codon 600
(V600E, previously called V599E; V600K, V600R). Cycling temperatures were set
to 94 °C (2 min), 60 °C (30 s) and 72 °C (2 min) for one cycle; 94 °C (15 s), 60 °C
(30 s) and 72 °C (20 s) for 14 cycles; 94 °C (15 s), 60 °C (30 s) and 72 °C (30 s) for 24
cycles and an additional ﬁnal extension step at 72 °C (2 min). The PCR primers for
NRAS exon 3 codon 61 analysis were: forward 5′-GGCAAATACACA-
GAGGAAGC-3′ and reverse 5′-ACCCCCAGGATTCTTACAGA-3′ encompassing
the common mutations of codon 61: Q61K and Q61R. The PCR cycler was set to
94 °C (2 min), 63 °C (30 s) and 72 °C (2 min) for one cycle; 94 °C (15 s), 63 °C (30 s)
and 72 °C (20 s) for 14 cycles; 94 °C (15 s), 63 °C (30 s) and 72 °C (30 s) for 24
cycles and an additional ﬁnal extension step at 72 °C (2 min). PCR products were
sent for sequencing to Sequiserve (Vatterstetten).
The mutation assay was established using single cells or genomic DNA of cell
lines with known exon 15 mutation c1799T>A (BRAF) and exon 3 mutation
c181C>A (NRAS). The mutant BRAF allele was detected in 62% (70–61), 84%
(MelHo) of detected sequences over all analysed single cells and in 61% (70–61)
and 86% (MelHo) in bulk genomic DNA. The mutation NRAS allele was present in
59% of all single cells and 46% of the bulk genomic DNA.
When several areas of the PT were microdissected or several DCCs were
isolated, the PT or DCCs were called positive if one of the areas or DCCs
harboured the BRAF or NRAS mutation.
Assessment of the allelic drop-out rate. To determine the allelic drop-out rate
(ADO) for BRAF/NRAS mutational analysis of single cells, 10.000 melanoma cell
line cells of known BRAF/NRAS mutational status were added to lymph nodes of
healthy controls and mechanically disaggregated and stained for immunocytology
as described in the section 'Lymph node disaggregation and immunocytology'.
Single cells were isolated, WGA performed and the allelic frequency of the BRAF
and NRAS mutations in individual cells was determined as described in the cor-
responding sections above. To determine the ADO in single cells from human
primary tumours or DCC-derived xenografts of patients with known mutational
BRAF/NRAS status, tumour tissue was digested with collagenase (0.33 µg/ml,
Sigma-Aldrich) and DNAseI (0.1 mg/ml Roche) to obtain a single-cell suspension.
After gp100-staining, individual cells and cell pools were manually isolated, WGA
performed and the allelic frequency of the BRAF and NRAS mutations was
determined as described in the corresponding sections above.
Statistical analysis. Unless otherwise stated, statistical signiﬁcance was assumed
for p< 0.05, with all tests performed two-sided.
Statistical methods for the analysis of dissemination and colonisation: To
determine the proportion of disseminating and colonising tumours as a function of
tumour thickness, the data were ﬁtted non-parametrically by maximum-likelihood
according to the iterative method of Turnbull55 for interval-censored data for the
following reason: for a patient with a certain tumour thickness, it can be observed
only whether dissemination or colonisation has occurred but the exact tumour
thickness at the time when the event occurred, or would occur, remains unknown.
If the event has occurred, the tumour thickness at the time of the event was at least
zero and at most equal to the tumour thickness at the time of observation. If the
event has not yet occurred, the lower limit of the tumour thickness is known. This
situation is identical to survival analysis when all the observations are interval
censored, for which a nonparametric maximum-likelihood-estimator is suggested
as by Turnbull55. Both nonparametric distributions are summarised by parametric
models that allow a better interpretation of the data. Therefore, we ﬁtted the
following ﬁve distributions: (1) standard log-logistic, (2) exponential, (3) log-
normal, (4) Weibull and (5) Fréchet. For the dissemination data, we introduced in
addition a parameter, which estimates the maximum proportion of patients who
disseminate. The parameters of the distributions were ﬁtted by maximum-
likelihood, taking into account interval censoring. We also estimate the 95%
conﬁdence intervals of the distributions, from which we derive the 95% conﬁdence
intervals of certain quantiles. The selection of the best model is based on the Bayes
information criterion (BIC), which takes into account the likelihood function, the
number of parameters and the number of observations. The goodness of ﬁt of the
models was assessed by grouping the 1027 values of tumour thickness for
dissemination into deciles and the 525 values of tumour thickness for colonisation
into quintiles. The observed number of patients with a positive event was compared
with the ﬁtted number of events by a χ2 statistic. The goodness-of-ﬁt test takes into
account the number of categories (ten for dissemination, ﬁve for colonisation) and
the number of estimated parameters. All ﬁve models yield a good ﬁt to the data, but
we adopt the simplest models with the minimum number of parameters.
The hazard rate describes the instantaneous risk for an event (dissemination
and colonisation) for those tumours, for which the event has not yet occurred. It
can be calculated explicitly by the density of the ﬁtted distribution divided by the
exceedance probability, which is obtained by subtracting the cumulative
distribution function from 1.
Comparison of PTs and DCCs: The frequency statistics of gains and losses
between PTs and DCCs were determined with a Mann–Whitney U test. Statistical
signiﬁcance for BRAF/NRAS mutations in paired PTs and DCCs was determined
with Fisher’s exact test.
Identiﬁcation of mutational patterns: Aberration/mutation patterns that
discriminate between PTs and DCCs, DCCs from patients with different DCCD
and thickness values, as well as with and without BRAF/NRAS mutations were
identiﬁed by Fisher’s exact test. Only loci with high enough cross-sample standard
deviation (>0.25) allowing for sufﬁcient class discrimination were considered. In
Fig. 2b, only the ten most variable loci in terms of the maximum variance across
samples without accounting for PT/DCC class labels were included. Multiple
testing corrections (across loci/mutations) were derived according to Benjamini
and Hochberg (FDR).
Identiﬁcation of discriminating mutations: To identify the thickness at which
critical alterations may have been acquired within the PT, we split DCCs of pre-
colonisation samples (deﬁned by a DCCD ≤ 105, see below) into two groups
according to the measured thickness values and identiﬁed genomic alterations that
clearly showed non-random distributions across these groups, i.e., lead to low
Fisher’s exact test p values. DCCD and thickness thresholds associated with low p
values might indicate PT sizes and genomic alterations that facilitate direct
dissemination to SLNs. We tested all DCCD thresholds up to 105 to deﬁne the
population of DCCs before colonisation and found evidence for statistical
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02674-y ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:595 |DOI: 10.1038/s41467-017-02674-y |www.nature.com/naturecommunications 15
differences for certain thickness thresholds and DCCD limits (Fig. 5b); however,
none reached 5% signiﬁcance.
An equivalent approach was taken to determine limiting DCCD thresholds and
genetic alterations that mark the transition from early DCCs to colony-forming
DCCs in the SLN. We asked for each genetic region at which DCCD it would split
all DCCs into two groups that signiﬁcantly differ in their distribution of gains and
losses. This DCCD would then separate DCCs with and without that speciﬁc
alteration and indicate the DCCD at which an alteration critical for disease
progression has been acquired (Fig. 7b).
Hierarchical cluster analyses (Fig. 2b and Supplementary Figure 5) were
performed using Euclidean distance and complete linkage. Analyses were
conducted using R (version 3.3.1, http://www.R-project.org) or JMP (http://www.
jmp.com).
Survival analysis: All survival statistics and tumour-free time of xenografts were
calculated using a log-rank test (JMP, IBM SPSS Statistics 20 for Windows or
GraphPad Prism 6.0 software for OSX).
Data availability. The data sets generated during and/or analysed during the
current study are available from the corresponding author on reasonable request.
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